Trial Profile
A randomized, double-blind, placebo-controlled study of single ascending doses of PTG-300 in normal healthy male subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jun 2018
Price :
$35
*
At a glance
- Drugs Rusfertide (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Protagonist Therapeutics
- 18 Jun 2018 According to a Protagonist Therapeutics media release, data from this study were presented at the 23rd Congress of the European Hematology Association (EHA)
- 14 Dec 2017 Status changed from recruiting to completed, according to a Protagonist Therapeutics media release.
- 14 Dec 2017 Results, which included the successful completion of the study extension of two dose cohorts, published in a Protagonist Therapeutics Media Release.